上海皓元医药股份有限公司 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》和《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》（以下简称"《自律监管指引 1 号》"）的规 定，将上海皓元医药股份有限公司（以下简称"本公司"或"公司"）2025 年 半年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）2024 年度向不特定对象发行可转换公司债券实际募集资金金额和资 金到账时间 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2024]1289号）同意，公司向不 特定对象发行82,235.00万元的可转换公司债券，期限6年，每张面值为人民币100元， 发 行 数 量为822,350 手（ 8,223,500 张）。 本次发 行的募集资 金总额 为人民 币 （特殊普通合伙）于2024年12月5日出具了《验资报告》（容诚验字[2024]200Z0069 号）。 公司对募集资金采用专户存储，设 ...

Core Viewpoint - The company has decided to postpone the expected completion date for its fundraising project related to the issuance of convertible bonds, specifically the "265t/a high-end pharmaceutical intermediate product project," to April 2026 due to various implementation challenges and market conditions [1][4][6]. Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - The total investment amount for the fundraising project is RMB 863.51 million, with RMB 811.74 million planned to be funded from the raised capital [2][3]. Project Delay Details - The delay in the project is attributed to the need for the company to ensure that the new construction of the third workshop is completed before starting renovations on the first and second workshops, which are critical for transitioning from commissioned processing to self-production [4][5]. - The expected completion date for the project has been postponed from March 2025 to April 2026 due to the late arrival of the raised funds and the need to optimize project progress in response to market demands [5][6]. Impact of Delay - The postponement is a cautious decision based on the actual situation of project implementation and does not alter the investment content or total amount, nor does it significantly impact the company's normal operations [4][6]. - The decision has been reviewed and approved by both the board of directors and the supervisory board, ensuring compliance with relevant regulations and protecting shareholder interests [6][7].